Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.62 |
| ▸ | TRPV1 | Q8NER1 | 19/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740228 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL3744553 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL3744558 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9TRPM8TRPV1 | |
| Hydrochloric Acid SCHEMBL3751795 | 0.90 | CYP3A4 (0.50) | CYP3A4CYP2C9TRPM8TRPV1 | |
| Hydrochloric Acid SCHEMBL3751798 | 0.90 | CYP3A4 (0.50) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL3740565 | 0.86 | TRPM8 (0.67) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL3740562 | 0.86 | TRPM8 (0.67) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL3744235 | 0.85 | CYP2C9 (0.85) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL2772149 | 0.85 | CYP2C9 (0.85) | CYP3A4CYP2C9TRPM8TRPV1 | |
| SCHEMBL3742908 | 0.84 | CYP3A4 (0.62) | CYP3A4CYP2C9TRPM8TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | claimed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | claimed |
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | disclosed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | CYP3A4 2735/4885CYP2C9 2805/4885TRPM8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.